Trial of the Route of Early Nutritional Support in Critically Ill Adults


ABSTRACT

BACKGROUND
Uncertainty exists about the most effective route for delivery of early nutritional support in critically ill adults. We hypothesized that delivery through the parenteral route is superior to that through the enteral route.

METHODS
We conducted a pragmatic, randomized trial involving adults with an unplanned admission to one of 33 English intensive care units. We randomly assigned patients who could be fed through either the parenteral or the enteral route to a delivery route, with nutritional support initiated within 36 hours after admission and continued for up to 5 days. The primary outcome was all-cause mortality at 30 days.

RESULTS
We enrolled 2400 patients; 2388 (99.5%) were included in the analysis (1191 in the parenteral group and 1197 in the enteral group). By 30 days, 393 of 1188 patients (33.1%) in the parenteral group and 409 of 1195 patients (34.2%) in the enteral group had died (relative risk in parenteral group, 0.97; 95% confidence interval, 0.86 to 1.08; P = 0.57). There were significant reductions in the parenteral group, as compared with the enteral group, in rates of hypoglycemia (44 patients [3.7%] vs. 74 patients [6.2%]; P = 0.006) and vomiting (100 patients [8.4%] vs. 194 patients [16.2%]; P < 0.001). There were no significant differences between the parenteral group and the enteral group in the mean number of treated infectious complications (0.22 vs. 0.21; P = 0.72), 90-day mortality (442 of 1184 patients [37.3%] vs. 464 of 1188 patients [39.1%]; P = 0.40), in rates of 14 other secondary outcomes, or in rates of adverse events. Caloric intake was similar in the two groups, with the target intake not achieved in most patients.

CONCLUSIONS
We found no significant difference in 30-day mortality associated with the route of delivery of early nutritional support in critically ill adults. (Funded by the United Kingdom National Institute for Health Research; CALORIES Current Controlled Trials number, ISRCTN17386141.)

* A complete list of the investigators and committee members in the CALORIES trial is provided in the Supplementary Appendix, available at NEJM.org.

This article was published on October 1, 2014, at NEJM.org.

DOI: 10.1056/NEJMo1409860
Copyright © 2014 Massachusetts Medical Society.
NUTRITIONAL SUPPORT IS STANDARD for critically ill patients and requires a complex calculus of timing, route of delivery, and the amount and type of nutrients that are administered — all of which may affect patient outcomes. The interpretation of published meta-analyses of trials comparing nutritional support through the parenteral route versus the enteral route in critically ill patients is complicated by small sample sizes, variable quality, selection bias, lack of standardized definitions, and interventions that combine multiple elements of nutritional support (e.g., timing and route). Currently, the enteral route is the mainstay, largely on the grounds of physiological rationale and modest evidence suggesting an association with fewer infections, yet it can also be associated with gastrointestinal intolerance and underfeeding. The parenteral route, though more invasive, more often secures delivery of the intended nutrition but has been associated with greater risks and rates of complications. However, these studies have not considered improvements in delivery, formulation, and monitoring of parenteral nutrition.

Although recent studies have evaluated supplemental parenteral nutrition, the most effective route for early nutritional support in critically ill patients is unknown. In the CALORIES trial, we tested the hypothesis that the parenteral route is superior to the enteral route for the delivery of early nutritional support in adults who had an unplanned admission to an intensive care unit (ICU) and who could be fed through either route.

METHODS

STUDY DESIGN AND OVERSIGHT

Our study was a pragmatic, open, multicenter, parallel-group, randomized, controlled trial. The North West London Research Ethics Committee approved the study protocol, which is available with the full text of this article at NEJM.org. The United Kingdom National Institute for Health Research funded the study and convened a trial steering committee and independent data and safety monitoring committee. The Clinical Trials Unit at the U.K. Intensive Care National Audit and Research Centre (ICNARC) managed the study (for details, see the Supplementary Appendix, available at NEJM.org).

SITES AND PATIENTS

The study was conducted in 33 adult general ICUs in England participating in the national clinical audit for adult critical care coordinated by ICNARC. Patients who were at least 18 years of age were eligible if they were expected to require nutritional support for at least 2 days, as determined by a clinician within 36 hours after an unplanned ICU admission that was expected to last at least 3 days. Patients were excluded if they could not be fed through either the parenteral or the enteral route, had received nutritional support in the past 7 days, had a gastrostomy or jejunostomy in situ, were pregnant, or were not expected to be in the United Kingdom for the next 6 months. (A detailed list of inclusion and exclusion criteria is provided in the Supplementary Appendix.) All patients or their consultees provided written informed consent or agreement according to the provisions of the United Kingdom Mental Capacity Act of 2005.

Using a 24-hour telephone randomization system, we assigned patients in a 1:1 ratio to receive early nutritional support through the parenteral route or the enteral route. We used a computerized minimization algorithm with a random component to balance patients according to ICU, age (<65 years or ≥65 years), surgical status (surgery <24 hours before ICU admission or no surgery <24 hours before ICU admission), and the presence or absence of severe malnutrition.

STUDY INTERVENTIONS

Nutritional support was initiated as soon as possible after randomization (within 36 hours after admission) and used exclusively for 5 days (120 hours) or until transition to exclusive oral feeding, discharge from the ICU, or death (termed the intervention period). Oral feeding could be initiated if clinically indicated during the intervention period. Patients in the parenteral group received nutrition through a central venous catheter with a dedicated lumen positioned in accordance with National Health Service guidelines. Patients in the enteral group received nutrition through a nasogastric or nasojejunal tube positioned in accordance with U.K. guidelines.

Energy targets were set at 25 kcal per kilogram of actual body weight per day, with a goal of reaching the target within 48 to 72 hours. Protein or amino acid targets were set according to local practice. Glycemic control was main-
tained in accordance with international guidelines (with a target level for serum glucose of <180 mg per deciliter [10 mmol per liter]). Calories from non-nutritional sources (e.g., propofol) were included in the calculations of total calories. All other treatments and nutritional support were provided according to local practice guidelines and at the clinicians’ discretion. (Details about the study interventions are provided in the Supplementary Appendix.)

OUTCOME MEASURES

We report the evaluation of clinical effectiveness, including the primary outcome at 30 days and all secondary outcomes within 90 days after randomization. The primary outcome was all-cause mortality at 30 days. Secondary outcomes were the duration of organ support, treated infectious and noninfectious complications, length of stay in the ICU and hospital, the duration of survival, and mortality at the time of discharge from the ICU and from the hospital, at 90 days, and at 1 year. Adverse events were monitored for 30 days. (Definitions for all outcomes are provided in the Supplementary Appendix.)

STATISTICAL ANALYSIS

We assumed a baseline 30-day mortality of 32% for patients receiving nutrition through the enteral route. On the basis of our updated meta-analysis, we estimated that the patients in the parenteral group, as compared with those in the enteral group, would have a potential relative risk reduction of approximately 20% in the primary outcome (Fig. S1 in the Supplementary Appendix). On the basis of these estimates, we determined that an enrollment of 2400 patients would have a power of 90% to detect a 20% relative risk reduction (absolute risk reduction, 6.4 percentage points) in the parenteral group with a two-sided alpha level of 0.05, assuming that 2% of patients would cross over to the other group or have a protocol violation and that 2% of patients would be lost to follow-up or withdraw from the study.17

A single, planned interim analysis was performed and was reviewed by the data and safety monitoring committee at the point when 30-day outcomes for the first 1200 patients were available. A Haybittle–Peto stopping rule (P<0.001) was used to guide recommendations for early termination.18 We performed all statistical analyses using the intention-to-treat principle on the basis of a prespecified statistical analysis plan. A P value of 0.05 was considered to indicate statistical significance. All tests were two-sided, and there was no adjustment for multiple variables. Continuous variables are reported as means and standard deviations or as medians and interquartile ranges. Categorical variables are reported as proportions. The time to the initiation of exclusive oral feeding was analyzed as the time to event, with censoring of data for all patients who died while receiving nutritional support.

We used Fisher’s exact test to compare between-group differences in the primary outcome. Absolute and relative risks are reported with 95% confidence intervals without adjustment. Reported as a secondary analysis is the adjusted odds ratio from multilevel logistic regression after adjustment for age, ICNARC Physiology Score, surgical status, degree of malnutrition, and a site-level random effect. A sensitivity approach was taken for missing data with respect to the primary outcome by assuming that all patients with missing outcomes survived in the enteral group and died in the parenteral group, with the analyses then repeated with the opposite assumptions. Missing baseline data were imputed in adjusted analyses with the use of multivariate imputation by means of chained equations.21

For secondary outcomes, we used Fisher’s exact test to analyze binary outcomes, t-tests to analyze the number of infectious complications and duration of organ support (with bootstrapping for anticipated non-normality in the latter22), and Wilcoxon rank-sum tests to analyze the length of stay, stratified according to survival. Unadjusted relative risks and adjusted odds ratios are reported for all mortality outcomes. We used the log-rank test to compare Kaplan–Meier curves for 90 days with no adjustment and a Cox proportional-hazards model to compare survival with adjustment.

The likelihood-ratio test was used to assess interactions between groups and prespecified subgroups in adjusted multilevel logistic-regression models. Subgroups were defined according to age quartiles, the presence or absence of malnutrition, quartiles of predicted risk of death,20,23 the presence or absence of mechanical ventilation, the presence or absence of cancer, and the
time from ICU admission to the initiation of nutritional support (<24 hours or ≥24 hours).

We repeated the primary analysis after adjustment for adherence using a structural-mean model\(^{24}\) with an instrumental variable for the study group, assuming a linear relationship between the degree of adherence (proportion of the intervention period that the assigned route...
was used) and treatment effect to estimate the efficacy of early nutritional support delivered through the parenteral route, as compared with the enteral route. All analyses were performed with the use of Stata/SE software, version 13.0.

RESULTS

PATIENTS
From June 22, 2011, to March 2, 2014, we screened 11,108 patients at 33 sites in England (Table S1 in the Supplementary Appendix). Of these patients, 2400 were enrolled, including 12 patients who subsequently withdrew from the study (Table S2 in the Supplementary Appendix), which resulted in an intention-to-treat population of 2388 patients (1191 in the parenteral group and 1197 in the enteral group) (Fig. 1). Baseline characteristics of the patients were similar in the two study groups (Table 1, and Table S3 in the Supplementary Appendix).

ADHERENCE AND NUTRITIONAL SUPPORT
Overall, 97% of the patients received early nutritional support through the assigned route, and rates of nonadherence to the protocol were similar in the two groups (Table 2). Initiation was delayed for 37 patients (3.1%) in the parenteral group and 41 (3.4%) in the enteral group. Cross-over occurred in 81 patients (6.8%) in the parenteral group and 18 patients (1.5%) in the enteral group during the intervention period; most of the crossover occurred toward the end of the 120 hours. Patients in the enteral group were more likely than those in the parenteral group to have complete days without nutrition (Table S4 and Fig. S2 in the Supplementary Appendix).

Nutritional support was initiated early and is summarized in Table 2 and in Tables S5 and S6 in the Supplementary Appendix. In the enteral group, the mean gastric residual volume (253 ml per 24 hours, with cutoff volumes of 200 to 500 ml in local protocols) was higher and more patients received prokinetic agents than in the parenteral group. Scores on the Sequential Organ Failure Assessment (SOFA)26 and amounts of calories and proteins or amino acids are provided in Figure 2. The target nutritional value of 25 kcal per kilogram per day was not achieved for the majority of patients in the two study groups, although caloric intake was similar in the two groups.

ADVERSE EVENTS
One or more serious adverse events were reported in 58 patients (4.9%) in the parenteral group and 58 patients (4.8%) in the enteral group (P=1.00) (Table 2, and Table S7 in the Supplementary Appendix). There were five serious, unexpected adverse events that were deemed by the site investigator to be potentially related to the study treatment in 4 patients (1 with ischemic bowel and hypoglycemia and 1 each with upper gastrointestinal hemorrhage and anterolateral myocardial infarction in the parenteral group and 1 with lower gastrointestinal hemorrhage in the enteral group).

PRIMARY OUTCOME
By 30 days, 393 of 1188 patients (33.1%) in the parenteral group and 409 of 1195 patients (34.2%) in the enteral group had died, with no significant between-group difference, even after adjustment for baseline variables (relative risk in the parenteral group, 0.97; 95% confidence interval [CI], 0.86 to 1.08; absolute risk reduction, 1.15; 95% CI, −2.65 to 4.94; P=0.57) (Table 3). The results were similar after the inclusion of 5 patients with missing data for the 30-day outcome (relative risks, 0.96 and 0.97 after the application of extreme assumptions).

SECONDARY OUTCOMES
There were significant reductions in the parenteral group, as compared with the enteral group, in rates of hypoglycemia (44 patients [3.7%] vs. 74 patients [6.2%]; absolute risk reduction, 2.5 percentage points; 95% CI, 0.8 to 4.2; P=0.006) and vomiting (100 patients [8.4%] vs. 194 patients [16.2%]; absolute risk reduction, 7.8 percentage points; 95% CI, 5.2 to 10.4; P<0.001). However, there were no significant differences between the parenteral group and the enteral group for the 16 other secondary outcomes, including the mean number of infectious complications (0.22 vs. 0.21; difference, 0.01; 95% CI, −0.04 to 0.06; P=0.72) and 90-day mortality (442 of 1184 patients [37.3%] vs. 464 of 1188 patients [39.1%]; relative risk, 0.96; 95% CI, 0.86 to 1.06; P=0.40) (Table 3, and Table S8 in the Supplementary Appendix). There was no significant difference in the duration of survival up to 90 days (P=0.98 by the log-rank test; adjusted hazard ratio, 0.94; 95% CI, 0.82 to 1.07, P=0.33) (Fig. S3 in the Supplementary Appendix).
### Table 1. Characteristics of the Patients at Baseline.*

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Parenteral Group (N = 1191)</th>
<th>Enteral Group (N = 1197)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age — yr</td>
<td>63.3±15.1</td>
<td>62.9±15.4</td>
</tr>
<tr>
<td>Male sex — no. (%)</td>
<td>689 (57.9)</td>
<td>725 (60.6)</td>
</tr>
<tr>
<td>Severe coexisting illness — no./total no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>29/1181 (2.5)</td>
<td>34/1193 (2.8)</td>
</tr>
<tr>
<td>Renal</td>
<td>20/1181 (1.7)</td>
<td>15/1193 (1.3)</td>
</tr>
<tr>
<td>Respiratory</td>
<td>34/1181 (2.9)</td>
<td>23/1193 (1.9)</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>11/1181 (0.9)</td>
<td>14/1193 (1.2)</td>
</tr>
<tr>
<td>Immunodeficiency</td>
<td>78/1181 (6.6)</td>
<td>95/1193 (8.0)</td>
</tr>
<tr>
<td>Surgery &lt;24 hr before ICU admission — no. (%)†</td>
<td>162 (13.6)</td>
<td>167 (14.0)</td>
</tr>
<tr>
<td>APACHE II‡</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute Physiology Score</td>
<td>15.1±6.2</td>
<td>15.2±6.2</td>
</tr>
<tr>
<td>Total score</td>
<td>19.6±6.9</td>
<td>19.6±7.0</td>
</tr>
<tr>
<td>Median predicted risk of death (IQR)§</td>
<td>0.34 (0.18–0.52)</td>
<td>0.34 (0.18–0.52)</td>
</tr>
<tr>
<td>ICNARC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physiology Score¶</td>
<td>25.6±8.0</td>
<td>25.8±7.8</td>
</tr>
<tr>
<td>Median predicted risk of death (IQR)‖</td>
<td>0.42 (0.22–0.65)</td>
<td>0.43 (0.23–0.65)</td>
</tr>
<tr>
<td>Mechanical ventilation — no./total no. (%)</td>
<td>979/1178 (83.1)</td>
<td>993/1185 (83.8)</td>
</tr>
<tr>
<td>SOFA score**</td>
<td>9.5±3.4</td>
<td>9.6±3.3</td>
</tr>
<tr>
<td>Subjective assessment of severe malnutrition — no. (%)†</td>
<td>151 (12.7)</td>
<td>152 (12.7)</td>
</tr>
<tr>
<td>Actual or estimated body-mass index††</td>
<td>27.7±7.4</td>
<td>28.2±7.5</td>
</tr>
<tr>
<td>Degree of malnutrition — no./total no. (%)‡‡</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>74/1152 (6.4)</td>
<td>81/1161 (7.0)</td>
</tr>
<tr>
<td>Moderate</td>
<td>8/1152 (0.7)</td>
<td>10/1161 (0.9)</td>
</tr>
<tr>
<td>None</td>
<td>1070/1152 (92.9)</td>
<td>1070/1161 (92.2)</td>
</tr>
</tbody>
</table>

* Plus–minus values are means ±SD. There were no significant differences between the two groups. ICU denotes intensive care unit, and IQR interquartile range.
† This characteristic was included in the minimization algorithm.
‡ Scores for physiological function on the Intensive Care National Audit and Research Centre (ICNARC) model range from 0 to 100, with higher scores indicating a greater degree of organ failure. The SOFA score was calculated with the use of data obtained within 24 hours before randomization.
§ This value is the predicted risk of death before discharge from an acute care hospital in the United Kingdom on the basis of a 2013 recalibration. There were insufficient data to calculate the predicted risk of death for 29 patients in the parenteral group and 24 in the enteral group.
¶ Scores on the Sequential Organ Failure Assessment (SOFA) range from 0 to 24, with higher scores indicating a greater degree of organ failure. The SOFA score was calculated with the use of data obtained within 24 hours before randomization.
‖ The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. This value was based on estimated weight or height for 1552 patients (780 in the parenteral group and 772 in the enteral group) and was not available for 24 patients (14 in the parenteral group and 10 in the enteral group).
** A high degree of malnutrition was defined as a BMI of less than 18.5 or a weight loss of more than 10% over the previous 6 months, and a moderate degree of malnutrition was defined as a BMI of less than 20 and a weight loss of more than 5%.
Subgroup and Secondary Analyses

There were no significant interactions between study group and any prespecified subgroup with respect to 30-day mortality (P = 0.15 to P = 0.83) (Fig. S4 in the Supplementary Appendix). The results were similar after adjustment for nonadherence (relative risk of death at 30 days, 0.96; 95% CI, 0.85 to 1.09; P = 0.55).
Discussion

Our study showed that among adults with an unplanned ICU admission for whom early nutritional support could be provided through either the parenteral or the enteral route, there was no significant difference in mortality at 30 days according to the route of delivery. In addition, there was no significant interaction on the basis of age, the degree of existing malnutrition, the severity of illness, or the timing of the initiation of nutritional support. The enteral route was associated with significantly more episodes of hypoglycemia and vomiting, but there were no significant between-group differences in the duration of organ support, the number of infectious complications, the length of stay in the ICU or total hospital stay, or the duration of survival up to 30 days.
## Table 3. Primary and Secondary Outcomes.*

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Parenteral Group (N = 1191)</th>
<th>Enteral Group (N = 1197)</th>
<th>Absolute Difference between Groups (95% CI)</th>
<th>Relative Risk (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary outcome: death within 30 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>— no./total no. (%)</td>
<td>393/1188 (33.1)</td>
<td>409/1195 (34.2)</td>
<td>1.15 (−2.65 to 4.94)†</td>
<td>0.97 (0.86 to 1.08)‡</td>
<td>0.57§</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of days alive and free of specified organ support up to 30 days¶</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Free of advanced respiratory support</td>
<td>14.3±12.1</td>
<td>14.3±12.2</td>
<td>0.04 (−0.94 to 1.01)</td>
<td>0.94</td>
<td></td>
</tr>
<tr>
<td>Free of advanced cardiovascular support</td>
<td>18.9±13.5</td>
<td>18.5±13.6</td>
<td>0.41 (−0.63 to 1.53)</td>
<td>0.44</td>
<td></td>
</tr>
<tr>
<td>Free of renal support</td>
<td>19.1±13.9</td>
<td>18.8±14.0</td>
<td>0.26 (−0.85 to 1.47)</td>
<td>0.66</td>
<td></td>
</tr>
<tr>
<td>Free of neurologic support</td>
<td>19.2±13.8</td>
<td>18.9±14.0</td>
<td>0.34 (−0.81 to 1.36)</td>
<td>0.57</td>
<td></td>
</tr>
<tr>
<td>Free of gastrointestinal support</td>
<td>13.0±11.7</td>
<td>13.2±11.8</td>
<td>−0.12 (−1.05 to 0.80)</td>
<td>0.81</td>
<td></td>
</tr>
<tr>
<td>No. of treated infectious complications per patient‖</td>
<td>0.22±0.60</td>
<td>0.21±0.56</td>
<td>0.01 (−0.04 to 0.06)</td>
<td>0.72</td>
<td></td>
</tr>
<tr>
<td>Noninfectious complications — no./total no. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Episodes of hypoglycemia</td>
<td>44/1191 (3.7)***</td>
<td>74/1197 (6.2)††</td>
<td>2.49 (0.75 to 4.22)†</td>
<td>0.006§</td>
<td></td>
</tr>
<tr>
<td>Elevated liver enzymes</td>
<td>212/1191 (17.8)</td>
<td>179/1197 (15.0)</td>
<td>−2.85 (−5.81 to 0.12)‡</td>
<td>0.07§</td>
<td></td>
</tr>
<tr>
<td>Nausea requiring treatment</td>
<td>44/1191 (3.7)</td>
<td>53/1197 (4.4)</td>
<td>0.73 (−0.85 to 2.32)†</td>
<td>0.41§</td>
<td></td>
</tr>
<tr>
<td>Abdominal distention</td>
<td>78/1191 (6.5)</td>
<td>99/1197 (8.3)</td>
<td>1.72 (−0.38 to 3.82)†</td>
<td>0.12§</td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>100/1191 (8.4)</td>
<td>194/1197 (16.2)</td>
<td>7.81 (5.20 to 10.43)†</td>
<td>&lt;0.001§</td>
<td></td>
</tr>
<tr>
<td>New or substantially worsened pressure ulcers</td>
<td>181/1190 (15.2)</td>
<td>179/1195 (15.0)</td>
<td>−0.23 (−3.10 to 2.64)†</td>
<td>0.91§</td>
<td></td>
</tr>
<tr>
<td>Median no. of days in the ICU (IQR)‡‡</td>
<td>8.1 (4.0–15.8)</td>
<td>7.3 (3.9–14.3)</td>
<td></td>
<td>0.15</td>
<td></td>
</tr>
<tr>
<td>Median no. of days in acute care hospital (IQR)§§</td>
<td>17 (8–34)</td>
<td>16 (8–33)</td>
<td></td>
<td>0.32</td>
<td></td>
</tr>
<tr>
<td>Death — no./total no. (%)¶¶</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In the ICU</td>
<td>317/1190 (26.6)</td>
<td>352/1197 (29.4)</td>
<td>0.91 (0.80 to 1.03)</td>
<td>0.13§</td>
<td></td>
</tr>
<tr>
<td>In acute care hospital</td>
<td>431/1185 (36.4)</td>
<td>450/1186 (37.9)</td>
<td>0.96 (0.86 to 1.06)</td>
<td>0.44§</td>
<td></td>
</tr>
<tr>
<td>By 90 days</td>
<td>442/1184 (37.3)</td>
<td>464/1188 (39.1)</td>
<td>0.96 (0.86 to 1.06)</td>
<td>0.40§</td>
<td></td>
</tr>
</tbody>
</table>

* Plus-minus values are means ±SD.
† This value is the absolute risk reduction between event rates.
‡ The adjusted odds ratio from multiple logistic regression was 0.95 (95% CI, 0.79 to 1.13; P = 0.55).
§ This P value was calculated with the use of Fisher’s exact test.
¶ Data on the number of days alive and free of organ support were not available for 5 patients in the parenteral group and 2 in the enteral group.
‖ Infectious complications in 224 of 262 patients (85.5%) in the parenteral group and in 215 of 253 patients (85.0%) in the enteral group were confirmed on laboratory testing.
** A total of 25 these episodes occurred during the first 6 days, and the mean (±SD) of the lowest blood glucose levels was 57±15 mg per deciliter (3.2±0.8 mmol per liter).
†† A total of 48 of these episodes occurred during the first 6 days, and the mean of the lowest blood glucose levels was 54±15 mg per deciliter (3.0±0.8 mmol per liter).
‡‡ The number of days in the ICU was not available for 1 patient in the parenteral group.
§§ The numbers of days in an acute care hospital were not available for 6 patients in the parenteral group and 11 in the enteral group.
¶¶ The adjusted odds ratios from multiple logistic regression were 0.86 (95% CI, 0.71 to 1.04; P = 0.12) for death in the ICU, 0.93 (95% CI, 0.78 to 1.11; P = 0.43) for death in an acute care hospital, and 0.93 (95% CI, 0.77 to 1.11; P = 0.39) for death by 90 days.

*Plus-minus values are means ±SD.
†This value is the absolute risk reduction between event rates.
‡The adjusted odds ratio from multiple logistic regression was 0.95 (95% CI, 0.79 to 1.13; P = 0.55).
§This P value was calculated with the use of Fisher’s exact test.
¶Data on the number of days alive and free of organ support were not available for 5 patients in the parenteral group and 2 in the enteral group.
‖Infectious complications in 224 of 262 patients (85.5%) in the parenteral group and in 215 of 253 patients (85.0%) in the enteral group were confirmed on laboratory testing.
**A total of 25 these episodes occurred during the first 6 days, and the mean (±SD) of the lowest blood glucose levels was 57±15 mg per deciliter (3.2±0.8 mmol per liter).
††A total of 48 of these episodes occurred during the first 6 days, and the mean of the lowest blood glucose levels was 54±15 mg per deciliter (3.0±0.8 mmol per liter).
‡‡The number of days in the ICU was not available for 1 patient in the parenteral group.
§§The numbers of days in an acute care hospital were not available for 6 patients in the parenteral group and 11 in the enteral group.
¶¶The adjusted odds ratios from multiple logistic regression were 0.86 (95% CI, 0.71 to 1.04; P = 0.12) for death in the ICU, 0.93 (95% CI, 0.78 to 1.11; P = 0.43) for death in an acute care hospital, and 0.93 (95% CI, 0.77 to 1.11; P = 0.39) for death by 90 days.
90 days. The target delivery of 25 kcal per kilogram per day was not reached in a majority of the patients in each study group.

There is debate about both the route of delivery and the dose of clinically supplied nutrition, and the aim of our study was to address solely the question of route. Set in a real-world context, our study had two major findings. First, there was no significant difference in outcome between the two study groups. Although there was a trend toward more gastrointestinal side effects with the enteral route, the reported increase in infectious complications that have been associated with the parenteral route was not observed. Possible contributory reasons are improvements in current management of vascular access and prevention of ventilator-associated pneumonia, as well as developments in feeding technology. Second, there was no significant difference in effective nutritional delivery, since patients in the two groups did not receive the calorically targets. Although these findings are consistent with those of previous trials evaluating the enteral route in critically ill patients, the presumption is that the parenteral route is more reliable in guaranteeing delivery. Possible contributory reasons as to why the parenteral route did not meet its calorically target include lack of availability of nutritional product, content (the use of commercially available rather than individually titrated product), delivery (delays or interruptions in delivery for procedures, transfers, patient factors, etc.), and clinical preference. However, the amount of nutrition that was delivered was consistent with amounts in previous studies in which delivery also fell short of the target in this population, suggesting that there are substantial practical and organizational impediments for both routes of delivery, at least during an initial 5-day period. However, the similar between-group calorific intake reinforces the design of our study to focus on the evaluation of the delivery route uncomplicated by dose.

Our study was conducted in ICUs in England that had preexisting, established protocols for the delivery of parenteral and enteral nutrition, prevention of bloodstream infections and ventilator-associated pneumonia, and glycemic control. It was designed as a pragmatic effectiveness study and represents the reality of current critical care practice in the English National Health Service. Although the study had a large enrollment, the results are generalizable only to the specific population that we studied. It was rigorously conducted, with the study groups well balanced at baseline and early initiation of nutritional support, as intended. Blinding was deemed to be impractical and, although the primary outcome was objective, some of the secondary outcomes, though defined and objectively assessed, may have been more vulnerable to observer bias. We selected an objective, documented clinical definition of a new infection — one that was laboratory-confirmed or for which there was sufficient conviction to treat the patient. Though the measurement of the residual gastric volume has recently been questioned, the overall feeding performance through the enteral route in our study was similar to their findings, and the rates of vomiting and infectious complications in our study were lower.

How do our findings compare with those in other recent trials on nutritional support in the critically ill? In the Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients (EPaNIC) trial, which was conducted in two hospitals (seven units) recruiting patients who required parenteral nutrition and using tight glycemic control, investigators found an association between supplemental parenteral nutrition delivered within 48 hours after presentation and an increased number of infectious episodes and days of mechanical ventilation, less hypoglycemia, and no difference in 90-day mortality. These differences were found for subgroups of cardiac surgical patients and other critically ill patients. Post hoc analyses suggested a dose–response relationship between an increased amount of parenteral nutrition and an increased rate of infectious episodes. Despite important differences between our study and the EPaNIC trial and between the two study groups in EPaNIC, our results potentially support their hypothesis that among patients receiving early supplemental parenteral nutrition, the dose is more associated with harm than is the route of delivery. In a trial conducted at two sites, Heidigger et al. found no difference in the rate of infection between day 8 and day 28 among patients who started receiving individually optimized parenteral nutrition to supplement inadequate enteral intake on day 4 and patients receiving only enteral nutrition. In a trial conducted at 31 sites involving patients with relative
Early Nutritional Support in Critically Ill Adults

and protein or amino acid requirements for critically ill patients. We specifically did not compare an individualized enteral feeding regimen (that allows for increased amounts in patients who can tolerate enteral feeding) with its parenteral equivalent (with individualized monitoring of metabolic and protein balance). However, our findings suggest that early nutritional support through the parenteral route, as it is typically administered, is neither more harmful nor more beneficial than such support through the enteral route.

The views expressed in this article are those of the authors and do not necessarily reflect those of the Health Technology Assessment Program of the National Institute for Health Research, National Health Service, or the Department of Health.

Supported by a grant from the Health Technology Assessment Program of the United Kingdom National Institute for Health Research (project no. 07/52/03).

Ms. Bear reports receiving consulting fees from Nutricia, lecture fees from Nestle Nutrition, travel support from Nutricia and Baxter, and grant support through her institution from Corpak MedSystems UK; Ms. Segaran, receiving travel support from Abbott Nutrition; Dr. Beale, receiving consulting and lecture fees from Nestle Nutrition and grant support from Fresenius Kabi (all through his institution), and negotiating an unrestricted research grant from Nestle Nutrition (through the European Society of Intensive Care Medicine); and Dr. Mythen, receiving lecture fees from Fresenius Kabi and Baxter and grant support from Fresenius Kabi and holding a patent related to methods and apparatus for guiding medical care based on detected gastric function through Medical Defence Technologies. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

REFERENCES


The New England Journal of Medicine
Downloaded from nejm.org on October 3, 2014. For personal use only. No other uses without permission.
Copyright © 2014 Massachusetts Medical Society. All rights reserved.


Copyright © 2014 Massachusetts Medical Society.